Brand name
Dantrium, the original
We didn’t find a savings card or cash price from Dantrium’s maker. Ask the pharmacy for Dantrium’s cash price. With insurance, ask what your plan charges.
Generic name: dantrolene
Used for: Muscle stiffness (spasticity) from stroke, MS or spinal injury · Preventing malignant hyperthermia during anesthesia or surgery · 1 more
Lowest without a membership
$16.98 for 30 capsules delivered ($11.73 plus $5.25 shipping)
Generic dantrolene 25 mg from Cost Plus Drugs, by mail
Need it today? $20.05 for 30 capsules with the free Team Cuban Card, at pharmacies that take it. Get the free card and show it there.
See the price and get the cardFor 3 months at a time $23.96 for 90 capsules at Walgreens with the free Optum Perks coupon. Ask your prescriber to write it for 90 days.
Get the free Optum Perks couponWith a membership $6.20 for 30 capsules from Amazon Pharmacy, by mail ($139 a year).
Open Amazon PharmacyA regular generic has the same active ingredient as Dantrium, and the FDA requires it to work the same way.
Dantrium, the original
We didn’t find a savings card or cash price from Dantrium’s maker. Ask the pharmacy for Dantrium’s cash price. With insurance, ask what your plan charges.
The same medicine as Dantrium, without the brand name
The same medicine as Dantrium, without the brand name. Its NDC is the number that names the exact product: give it to the pharmacy and they can look it up or order it.
dantrolene
Pick your strength
Give the pharmacy this NDC
What to say at the pharmacy
“Before you fill my Dantrium, can you tell me what I’d pay for the brand, for the authorized generic from Par Health (NDC ), and for a regular generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
Source: FDA, updated November 16, 2026
Official labels and ingredient lists from DailyMed (U.S. National Library of Medicine).
25 mg capsule
Same active ingredient. Only the coloring is listed differently, so it may look different.
Active: dantrolene sodium 25 mg
Inactive, on both labels:
Only on the authorized generic’s label: Ferric oxide red, Ferric oxide yellow
50 mg capsule
Same active ingredient. Only the coloring is listed differently, so it may look different.
Active: dantrolene sodium 50 mg
Inactive, on both labels:
Only on the authorized generic’s label: Ferric oxide red, Ferric oxide yellow
100 mg capsule
Same active ingredient. Only the coloring is listed differently, so it may look different.
Active: dantrolene sodium 100 mg
Inactive, on both labels:
Only on the authorized generic’s label: Ferric oxide red, Ferric oxide yellow
Same active ingredient as Dantrium. Fillers and dyes can differ.
Pharmacies’ own cash prices for generic dantrolene, lowest first.
Pick up in storeDelivered
From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.
Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.
4 companies sell a generic of Dantrium that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
Has lactose · Has dyes: D&C Yellow No. 10, FD&C Green No. 3, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6 · Made by Impax Laboratories
25 mg Rich yellow opaque and light green opaque, capsule, 16 mm, marked “G441 / G441”
| Package | NDC |
|---|---|
| Bottle of 100 | 0115-4411-01 |
| Bottle of 500 | 0115-4411-02 |
| Bottle of 1000 | 0115-4411-03 |
50 mg Rich yellow opaque and light blue opaque, capsule, 18 mm, marked “G442 / G442”
| Package | NDC |
|---|---|
| Bottle of 100 | 0115-4422-01 |
| Bottle of 500 | 0115-4422-02 |
| Bottle of 1000 | 0115-4422-03 |
100 mg Rich yellow opaque and reddish orange opaque, capsule, 19 mm, marked “G443 / G443”
| Package | NDC |
|---|---|
| Bottle of 100 | 0115-4433-01 |
| Bottle of 500 | 0115-4433-02 |
| Bottle of 1000 | 0115-4433-03 |
Inactive ingredients: croscarmellose sodium, gelatin, lactose monohydrate, magnesium stearate, starch, corn, titanium dioxide, ferric oxide yellow, D&C Yellow No. 10, FD&C Green No. 3, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6
Has lactose · Has dyes: D&C Yellow No. 10, FD&C Blue No. 1, FD&C Blue No. 2, FD&C Red No. 40
25 mg Orange and yellow, capsule, 16 mm, marked “A / 219”
| Package | NDC |
|---|---|
| Bottle of 100 | 64850-840-01 |
50 mg Orange and yellow, capsule, 16 mm, marked “A / 220”
| Package | NDC |
|---|---|
| Bottle of 100 | 64850-841-01 |
100 mg Orange and yellow, capsule, 16 mm, marked “A / 221”
| Package | NDC |
|---|---|
| Bottle of 100 | 64850-842-01 |
Inactive ingredients: starch, corn, lactose monohydrate, magnesium stearate, talc, D&C Yellow No. 10, FD&C Red No. 40, gelatin, titanium dioxide, ferric oxide yellow, FD&C Blue No. 1, FD&C Blue No. 2, butyl alcohol, shellac, propylene glycol, ferrosoferric oxide
20 mg
| Package | NDC |
|---|---|
| Vial of 1 | 0143-9297-01 |
Inactive ingredients: mannitol, sodium hydroxide
Sold as Revonto
20 mg/60 mL
| Package | NDC |
|---|---|
| Carton of 360 mL | 78670-003-67 |
Inactive ingredients: mannitol, sodium hydroxide
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
In Chronic Spasticity:
Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.
If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium.
Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression.
A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself.
In Malignant Hyperthermia:
Oral Dantrium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous.
Oral Dantrium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.
Source: the FDA label for Dantrium (Par Health USA, LLC), August 25, 2026. Full label on DailyMed
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/dantrium/